Search results
Results from the WOW.Com Content Network
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
The mirvetuximab, which has been submitted for FDA approval, is being developed as a monotherapy or a standalone treatment for ovarian cancer. [7] [8] Other products currently in clinical-stage development include: [9] IMGN853, (mirvetuximab soravtansine) targeting FRα, and using DM4. [10] IMGN529, targeting CD37 for Non-Hodgkin lymphoma (NHL ...
Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
Iodine (125 I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[8]Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success.
For premium support please call: 800-290-4726 more ways to reach us
This page was last edited on 5 February 2023, at 17:24 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.